Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children

Alessandra Viganò, Grace M. Aldrovandi, Vania Giacomet, Marzia Merlo, Laura Martelli, Silvia Beretta, Paola Luraschi, Giuseppe Rombolà, Stefano Mora

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objective: To assess the impact on immunological, virological and metabolic parameters of replacing protease inhibitors (PIs) with efavirenz and replacing stavudine with tenofovir in HIV-infected children. Methods: A 48-week prospective evaluation of 28 HIV-infected children, with stable undetectable HIV-1 loads, who were taking highly active antiretroviral therapy (HAART) containing lamivudine, stavudine and a PI. Individuals were randomized to switch PI to efavirenz and stavudine to tenofovir at baseline (Group 1) or at week 24 (Group 2). Patient assessment included: clinical evaluation, viral load, CD4+ T-cell count, fasting blood levels and urine samples. Results: All individuals maintained HIV RNA + T-cell count through week 48. In Group 1 individuals, a significant decrease in cholesterol (P

Original languageEnglish
Pages (from-to)917-924
Number of pages8
JournalAntiviral Therapy
Volume10
Issue number8
Publication statusPublished - 2005

Fingerprint

Tenofovir
efavirenz
Stavudine
Dyslipidemias
Protease Inhibitors
HIV
T-Lymphocytes
Lamivudine
Highly Active Antiretroviral Therapy
CD4 Lymphocyte Count
Viral Load
HIV-1
Fasting
Cell Count
Cholesterol
Urine
RNA

ASJC Scopus subject areas

  • Pharmacology

Cite this

Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. / Viganò, Alessandra; Aldrovandi, Grace M.; Giacomet, Vania; Merlo, Marzia; Martelli, Laura; Beretta, Silvia; Luraschi, Paola; Rombolà, Giuseppe; Mora, Stefano.

In: Antiviral Therapy, Vol. 10, No. 8, 2005, p. 917-924.

Research output: Contribution to journalArticle

Viganò, A, Aldrovandi, GM, Giacomet, V, Merlo, M, Martelli, L, Beretta, S, Luraschi, P, Rombolà, G & Mora, S 2005, 'Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children', Antiviral Therapy, vol. 10, no. 8, pp. 917-924.
Viganò, Alessandra ; Aldrovandi, Grace M. ; Giacomet, Vania ; Merlo, Marzia ; Martelli, Laura ; Beretta, Silvia ; Luraschi, Paola ; Rombolà, Giuseppe ; Mora, Stefano. / Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. In: Antiviral Therapy. 2005 ; Vol. 10, No. 8. pp. 917-924.
@article{16f26526ee5646009d6075db85127d4e,
title = "Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children",
abstract = "Objective: To assess the impact on immunological, virological and metabolic parameters of replacing protease inhibitors (PIs) with efavirenz and replacing stavudine with tenofovir in HIV-infected children. Methods: A 48-week prospective evaluation of 28 HIV-infected children, with stable undetectable HIV-1 loads, who were taking highly active antiretroviral therapy (HAART) containing lamivudine, stavudine and a PI. Individuals were randomized to switch PI to efavirenz and stavudine to tenofovir at baseline (Group 1) or at week 24 (Group 2). Patient assessment included: clinical evaluation, viral load, CD4+ T-cell count, fasting blood levels and urine samples. Results: All individuals maintained HIV RNA + T-cell count through week 48. In Group 1 individuals, a significant decrease in cholesterol (P",
author = "Alessandra Vigan{\`o} and Aldrovandi, {Grace M.} and Vania Giacomet and Marzia Merlo and Laura Martelli and Silvia Beretta and Paola Luraschi and Giuseppe Rombol{\`a} and Stefano Mora",
year = "2005",
language = "English",
volume = "10",
pages = "917--924",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "8",

}

TY - JOUR

T1 - Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children

AU - Viganò, Alessandra

AU - Aldrovandi, Grace M.

AU - Giacomet, Vania

AU - Merlo, Marzia

AU - Martelli, Laura

AU - Beretta, Silvia

AU - Luraschi, Paola

AU - Rombolà, Giuseppe

AU - Mora, Stefano

PY - 2005

Y1 - 2005

N2 - Objective: To assess the impact on immunological, virological and metabolic parameters of replacing protease inhibitors (PIs) with efavirenz and replacing stavudine with tenofovir in HIV-infected children. Methods: A 48-week prospective evaluation of 28 HIV-infected children, with stable undetectable HIV-1 loads, who were taking highly active antiretroviral therapy (HAART) containing lamivudine, stavudine and a PI. Individuals were randomized to switch PI to efavirenz and stavudine to tenofovir at baseline (Group 1) or at week 24 (Group 2). Patient assessment included: clinical evaluation, viral load, CD4+ T-cell count, fasting blood levels and urine samples. Results: All individuals maintained HIV RNA + T-cell count through week 48. In Group 1 individuals, a significant decrease in cholesterol (P

AB - Objective: To assess the impact on immunological, virological and metabolic parameters of replacing protease inhibitors (PIs) with efavirenz and replacing stavudine with tenofovir in HIV-infected children. Methods: A 48-week prospective evaluation of 28 HIV-infected children, with stable undetectable HIV-1 loads, who were taking highly active antiretroviral therapy (HAART) containing lamivudine, stavudine and a PI. Individuals were randomized to switch PI to efavirenz and stavudine to tenofovir at baseline (Group 1) or at week 24 (Group 2). Patient assessment included: clinical evaluation, viral load, CD4+ T-cell count, fasting blood levels and urine samples. Results: All individuals maintained HIV RNA + T-cell count through week 48. In Group 1 individuals, a significant decrease in cholesterol (P

UR - http://www.scopus.com/inward/record.url?scp=30444446823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444446823&partnerID=8YFLogxK

M3 - Article

C2 - 16430197

AN - SCOPUS:30444446823

VL - 10

SP - 917

EP - 924

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 8

ER -